The WVU Heart and Vascular Institute is hosting a two-day symposium focused on exploring the benefits and long-term potential of robotic aortic valve replacement. Fans of the procedure say it represents a safe, effective alternative to TAVR and SAVR in patients with severe aortic stenosis. 

B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.

Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward. 

In fact, researchers wrote, MAC appears to influence a patient's odds of developing HFpEF even more than their BMI.

The patient's Trifecta GT heart valve had to be replaced after just six years, an experience he says resulted in "permanent injuries." Abbott pulled the devices off the U.S. market in 2023 due to a known risk of structural valve deterioration. 

Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.